The latest announcement is out from Bastide le Confort Medical ( (FR:BLC) ).
Groupe Bastide reported a positive performance in its 2024-2025 half-year results, with a recurring operating margin increase to 9.1% and a 10.5% rise in operating profit to €22.8 million. The company achieved organic growth of 8.5%, driven by strong performances in home healthcare services, particularly in the respiratory and diabetes sectors. The results reflect the successful implementation of measures to optimize margins and control costs, despite increased financial expenses due to debt refinancing.
More about Bastide le Confort Medical
Groupe Bastide is a leading European provider of home healthcare services, focusing on areas such as respiratory care, nutrition-perfusion-stomatherapy, and diabetes. The company has a strong market presence and is known for its technical business activities, which constitute a significant portion of its operations.
YTD Price Performance: 8.49%
Average Trading Volume: 447
Technical Sentiment Consensus Rating: Hold
Current Market Cap: €189.7M
For a thorough assessment of BLC stock, go to TipRanks’ Stock Analysis page.